These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 17325277)
1. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Hau P; Koch D; Hundsberger T; Marg E; Bauer B; Rudolph R; Rauch M; Brenner A; Rieckmann P; Schuth J; Jauch T; Koch H; Bogdahn U Neurology; 2007 Feb; 68(9):688-90. PubMed ID: 17325277 [TBL] [Abstract][Full Text] [Related]
2. Temozolomide in the treatment of recurrent malignant glioma. Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879 [TBL] [Abstract][Full Text] [Related]
3. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. Harris MT; Rosenthal MA; Ashley DL; Cher L J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571 [TBL] [Abstract][Full Text] [Related]
4. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? Wen PY J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652 [No Abstract] [Full Text] [Related]
5. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334 [TBL] [Abstract][Full Text] [Related]
6. Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Hassler M; Micksche M; Stockhammer G; Pichler J; Payer F; Abuja B; Deinsberger R; Marosi C Wien Klin Wochenschr; 2006 May; 118(7-8):230-8. PubMed ID: 16794761 [TBL] [Abstract][Full Text] [Related]
7. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Chan DT; Poon WS; Chan YL; Ng HK Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483 [TBL] [Abstract][Full Text] [Related]
9. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536 [TBL] [Abstract][Full Text] [Related]
10. Temozolomide in children with progressive low-grade glioma. Gururangan S; Fisher MJ; Allen JC; Herndon JE; Quinn JA; Reardon DA; Vredenburgh JJ; Desjardins A; Phillips PC; Watral MA; Krauser JM; Friedman AH; Friedman HS Neuro Oncol; 2007 Apr; 9(2):161-8. PubMed ID: 17347491 [TBL] [Abstract][Full Text] [Related]
11. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma. Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725 [TBL] [Abstract][Full Text] [Related]
12. Effects of palliative treatment with temozolomide in patients with high-grade gliomas. Ziobro M; Rolski J; Grela-Wojewoda A; Zygulska A; Niemiec M Neurol Neurochir Pol; 2008; 42(3):210-5. PubMed ID: 18651326 [TBL] [Abstract][Full Text] [Related]